CIK 0000946644 · Non-accelerated filer<br>Smaller reporting company
AIM ImmunoTech Inc.
Sign in to watch- Ticker
- AIM
- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 520845822
- Phone
- 352-448-7797
- Business address
- 2117 SW HIGHWAY 484, OCALA, FL, 32801
- Former names
- AIM ImmunoTech Inc., HEMISPHERX BIOPHARMA INC
- Open-market buys, last 90 days
- $39,251
- in 10 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$39,251. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-10 | Equels Thomas K CEO & President | Purchase | +39,000 | $0.14 | $5K | 293,095 |
| 2026-11-09 | Equels Thomas K CEO & President | Purchase | +31,298 | $0.16 | $5K | 254,095 |
| 2026-11-06 | Equels Thomas K CEO & President | Purchase | +12,751 | $0.16 | $2K | 222,797 |
| 2026-11-06 | Equels Thomas K CEO & President | Purchase | +20,299 | $0.16 | $3K | 210,046 |
| 2026-10-23 | Equels Thomas K CEO & President | Purchase | +31,675 | $0.16 | $5K | 189,747 |
| 2026-10-22 | Equels Thomas K CEO & President | Purchase | +31,250 | $0.16 | $5K | 158,072 |
| 2026-09-17 | Equels Thomas K CEO & President | Purchase | +24,000 | $0.21 | $5K | 126,822 |
| 2026-09-16 | Equels Thomas K CEO & President | Purchase | +11,000 | $0.21 | $2K | 102,822 |
| 2026-09-15 | Equels Thomas K CEO & President | Purchase | +22,000 | $0.22 | $5K | 91,822 |
| 2026-09-14 | Equels Thomas K CEO & President | Purchase | +5,900 | $0.22 | $1K | 69,822 |
| 2026-03-12 | Equels Thomas K CEO & President | Conversion | +25,000 | 63,922 | ||
| 2026-03-12 | Equels Thomas K CEO & President | Conversion · Series G Convertible Preferred Stock | −25 | 0 | ||
| 2026-03-12 | CHEMEROW DAVID I. Director | Conversion | +25,000 | 28,441 | ||
| 2026-03-12 | CHEMEROW DAVID I. Director | Conversion · Series G Convertible Prefered Stock | −25 | 0 | ||
| 2026-03-06 | Equels Thomas K CEO & President | Other acquisition · Series G Convertible Preferred Stock | +25 | $25,000.00 | $625K | 25 |
| 2026-03-06 | Equels Thomas K CEO & President | Other acquisition · Class G Warrants | +50,000 | 50,000 | ||
| 2026-03-06 | CHEMEROW DAVID I. Director | Other acquisition · Series G Convertible Preferred Stock | +25 | $25,000.00 | $625K | 25 |
| 2026-03-06 | CHEMEROW DAVID I. Director | Other acquisition · Class G Warrants | +50,000 | 50,000 | ||
| 2026-02-05 | CHEMEROW DAVID I. Director | Grant or award | +2,800 | $1.23 | $3K | 3,441 |
| 2025-06-13 | Equels Thomas K CEO & President | Purchase | +107 | $7.70 | $824 | 38,885 |
Page 1 of 14 · 263 trades